(S)-benzyl 2-amino-3-(benzyloxy)propanoate hydrochloride

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-benzyl 2-amino-3-(benzyloxy)propanoate hydrochloride
• 英文别名: (S)-Benzyl 2-amino-3-(benzyloxy)propanoate hydrochloride；benzyl (2S)-2-amino-3-phenylmethoxypropanoate;hydrochloride
• 化学式: C₁₇H₁₉NO₃*ClH
• 分子量: 321.804
• InChiKey: BGAVLJMLSSCOSD-NTISSMGPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  22
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  61.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (S)-benzyl 2-amino-3-(benzyloxy)propanoate hydrochloride 在 盐酸 、 1-羟基苯并三唑一水物 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 、 乙酸乙酯 为溶剂， 反应 32.5h， 生成 estradiol-3-O-acetyl-Arg(Nω-NO2)-Gly-Asp(OBn)-Ser(Bn)-OBn
  参考文献：
  名称：

  Improved Anti-Osteoporosis Potency and Reduced Endometrial Membrane Hyperplasia During Hormone Replacement Therapy with Estrogen−RGD Peptide Conjugates

  摘要：

  To improve the specificity and potency of estrogen replacement therapy therapeutics while also minimizing the side effects such as bone resorption and thickening of the uterine wall, a series of novel estrogen-derived conjugates estradiol-3-RGD, estradiol-17-RGD, and estrone-3-RGD peptides have been prepared. In a mouse model, intraperitoneal (i.p.) administration of these estrogen-RGD peptide conjugates resulted in decreased serum concentrations of calcium and alkaline phosphatase, as well as increased levels of calcium, phosphorus, and minerals in the mouse femur. Furthermore, the anti-osteoporosis action of these conjugates followed a dose-dependent manner and was accompanied with no observable effects on endometrial cell hyperplasia. In addition to all of these compounds exhibiting biological activity when administered by the i.p. route, we were particularly pleased to note that the estradiol-3-RGD and estradiol-17-RGD conjugates were both orally active.

  DOI：

  10.1021/jm070242a
• 作为产物：
  描述：

  N-BOC-O-苄基-L-丝氨酸 在 盐酸 、 caesium carbonate 作用下， 以 乙醇 、 水 、 乙酸乙酯 为溶剂， 反应 6.25h， 生成 (S)-benzyl 2-amino-3-(benzyloxy)propanoate hydrochloride
  参考文献：
  名称：

  RGD-peptides modifying dexamethasone: to enhance the anti-inflammatory efficacy and limit the risk of osteoporosis

  摘要：

  RGD肽修饰地塞米松可以增强其抗炎效力并限制骨质疏松症的风险。

  DOI：

  10.1039/c5md00215j

文献信息

• [EN] SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS SPIROLACTAMES D'UN RÉCEPTEUR NMDA ET LEURS UTILISATIONS
  申请人：NAUREX INC

  公开号：WO2014120783A1

  公开（公告）日：2014-08-07

  Disclosed are compounds having enhanced potency in the modulation of NMD A receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

  揭示了在调节NMDA受体活性方面具有增强效力的化合物。这些化合物可用于治疗抑郁症和相关疾病。此外，还披露了口服制剂和其他药用可接受的化合物给药形式，包括静脉注射制剂。
• [EN] SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS SPIRO-LACTAMES DES RÉCEPTEURS NMDA ET LEURS UTILISATIONS
  申请人：APTINYX INC

  公开号：WO2018026763A1

  公开（公告）日：2018-02-08

  Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

  揭示了具有调节NMDA受体活性潜力的化合物。这些化合物可用于治疗抑郁症和相关疾病。还公开了口服制剂和其他药学上可接受的化合物给药形式，包括静脉注射制剂。
• Synthesis, evaluation and 3D QSAR analysis of novel estradiol–RGD octapeptide conjugates with oral anti-osteoporosis activity
  作者：Jiangyuan Liu、Xiaoyi Zhang、Ming Zhao、Shiqi Peng

  DOI：10.1016/j.ejmech.2008.09.036

  日期：2009.4

  To enhance the potency, reduce the side effects and improve oral property of estradiol in estrogen replacement therapy (ERT), 6 novel estradiol–RGD octapeptide conjugates have been prepared. In an ovariectomized mouse osteoporotic model, at an oral dosage of 110.3 nmol/kg per day, their anti-osteoporosis activity was significantly higher than that of estradiol and estradiol–RGD tetrapeptide conjugates

  为了增强雌激素替代疗法（ERT）的效力，降低副作用并改善雌二醇的口服特性，已制备了6种新型雌二醇-RGD八肽偶联物。在卵巢切除的小鼠骨质疏松模型中，每天口服剂量为110.3 nmol / kg，它们的抗骨质疏松活性显着高于雌二醇和雌二醇-RGD四肽偶联物，它们的血栓形成和子宫内膜增生的风险明显低于雌二醇和雌二醇-RGD四肽共轭物的结合力。使用Cerius2的QSAR模块，对接受小鼠的雌二醇-RGD肽结合物的股骨重量和股骨灰分重量进行了3D QSAR。的[R 2 高达0.995和0.988的3D QSAR方程式表明，它们能够预测结合物的相对精确的抗骨质疏松活性。
• NOVEL COMPOUND WITH EFFECTS OF THROMBOLYSIS, FREE RADICAL SCAVENGING AND THROMBUS-TARGETING AS WELL AS PREPARATION METHOD AND USE THEREOF
  申请人：Shanghai Lumosa Therapeutics, Co., Ltd.

  公开号：US20150290339A1

  公开（公告）日：2015-10-15

  The present invention discloses a novel compound with effects of thrombolysis, free radical scavenging and thrombus-targeting, as well as a preparation method and use thereof. The compound is a ternary conjugate formed by conjugating a thrombolytic peptide, a free radical scavenger and a thrombus-targeting/antithrombotic peptide together via a linking arm. The present invention also discloses a pharmaceutical composition containing the compounds, wherein the compounds form a nanospherical structure.

  本发明公开了一种具有溶栓、清除自由基和靶向血栓作用的新型化合物，以及其制备方法和用途。该化合物是通过连接臂将溶栓肽、自由基清除剂和靶向/抗血栓肽结合在一起形成的三元共轭物。本发明还公开了含有这些化合物的药物组合物，其中这些化合物形成纳米球状结构。
• [EN] SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF<br/>[FR] SPIRO-LACTAME MODULATEUR DE RÉCEPTEURS NMDA ET LEURS UTILISATIONS
  申请人：APTINYX INC

  公开号：WO2019152688A1

  公开（公告）日：2019-08-08

  Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders as well as other disorders.

  披露了在调节NMDA受体活性方面具有潜力的化合物。这些化合物可用于治疗抑郁症和相关疾病以及其他疾病。